<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:03:11Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/32331" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/32331</identifier><datestamp>2026-09-24T19:51:31Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Papara, Lisa</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-09-19T17:52:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2025-09-19T17:52:54Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/32331</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/18298</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Multiple myeloma is a plasma cell malignancy with limited treatment options and a poor prognosis in those with relapsed/refractory disease. In recent years, adoptive transfer of genetically engineered T cells, such as chimeric antigen receptor (CAR)-T cell therapy has realized remarkable clinical responses in hematologic malignancies. The conventional CAR-T cell platform confers tumour antigen specificity of conventional T cells, known as αβ T cells, and these treatments have shown impressive response rates in individuals with relapsed/refractory myeloma. CAR-T cell therapy employs a patients’ own T cells (aka autologous therapy), which significantly reduces accessibility to patients as manufacturing is incredibly costly and lengthy. These challenges may be addressed by off-the-shelf T cell therapies that can be administered to patients on-demand at time of need. A non-conventional T cell population, known as γδ T cells, represent an attractive platform for an off-the-shelf T cell therapy as they can be safely transferred to unrelated hosts without the risk of developing graft-versus-host disease. The natural propensity of γδ T cells to kill myeloma cells can be markedly enhanced by genetic engineering to express synthetic receptors directed at common myeloma targets, such as B cell maturation antigen (BCMA).&#xd;
I have developed an in vitro model, allowing for the assessment of recursive stimulation of engineered γδ Τ cells in response to myeloma targets, to better understand the fundamental biology and long-term functionality of our cell product.&#xd;
In chapter I, I found that engineered γδ T cells can robustly expand upon primary stimulation to myeloma targets, however this response is ablated upon subsequent exposure. Upon further investigation, this work found that γδ Τ cells lose their ability to produce cytokine and to bind strongly to tumour targets following stimulation, which does not seem to be a result of impaired synthetic receptor signaling.&#xd;
In chapter II, I explored the effect of IL-15 supplementation during recursive stimulation and found that IL-15 was able to recover impaired expansion and proliferation of γδ T cells upon restimulation with myeloma targets.&#xd;
In chapter III, I investigated the use of PI3K and mTOR inhibitors during γδ T cell manufacturing to enrich T cells with more memory-like features. While these inhibitors were able to skew the cells towards higher memory, we did not observe improved functionality in the context of recursive stimulation.&#xd;
The work presented herein describes fundamental properties of γδ T cells in the context of anti-tumour immunity and presents potential methods by which to enhance their functionality and long-term persistence.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Health Sciences (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">T cells are critical components of the immune response, protecting humans from potential threats such as viruses and cancer. Significant advances in the field of cancer treatment employ T cells that are genetically engineered to better target a patients’ tumour cells, leading to destruction. While this approach has seen incredible clinical success, particularly in blood cancers, it is a highly personalized process causing it to be incredibly costly and lengthy, demonstrating the need for ‘off-the-shelf’ solutions. We propose the use of an unconventional T cell subset as the cellular substrate for this approach, which can safely bypass the need for personalized cell-based therapy. We explored the functionality of these genetically engineered unconventional T cells as a potential cell- based therapeutic for multiple myeloma, a blood cancer that is largely considered ‘incurable’.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunotherapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Gamma-delta T cell</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">T cell engineering</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Developing an ‘Off-the-Shelf’ Engineered γδ T Cell Therapy for Multiple Myeloma</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>